G K Wilcock

Summary

Affiliation: University of Bristol
Country: UK

Publications

  1. ncbi request reprint Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease
    Z K van Helmond
    Dementia Research Group, Institute of Clinical Neurosciences, Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Bristol, UK
    Neuropathol Appl Neurobiol 33:317-27. 2007
  2. ncbi request reprint Dementia with Lewy bodies
    G K Wilcock
    Department of Care of the Elderly, University of Bristol, Frenchay Hospital, BS16 1LE, Bristol, UK
    Lancet 362:1689-90. 2003
  3. ncbi request reprint Memantine for the treatment of dementia
    Gordon K Wilcock
    Department of Care of the Elderly, University of Bristol, UK
    Lancet Neurol 2:503-5. 2003
  4. pmc Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group
    G K Wilcock
    Department of Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol BS16 1LE
    BMJ 321:1445-9. 2000
  5. ncbi request reprint The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials
    G K Wilcock
    Department of Care of the Elderly, University of Bristol, UK
    Int J Geriatr Psychiatry 17:175-83. 2002
  6. ncbi request reprint Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor
    P H Holden
    Department of Medicine Care of the Elderly, Bristol Royal Infirmary, UK
    Nat Biotechnol 15:668-72. 1997
  7. ncbi request reprint How are quality of life ratings made? Toward a model of quality of life in people with dementia
    L M T Byrne-Davis
    Department of Care of the Elderly, Department of Clinical Science at North Bristol, University of Bristol, UK
    Qual Life Res 15:855-65. 2006
  8. ncbi request reprint APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein
    K Chalmers
    Department of Care of the Elderly, Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK
    Neuropathol Appl Neurobiol 29:231-8. 2003
  9. ncbi request reprint Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease
    S Williams
    Care of the Elderly, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Bristol, UK
    Neuropathol Appl Neurobiol 31:414-21. 2005
  10. ncbi request reprint Neuronal death in brain infarcts in man
    S Love
    Departments of Neuropathology, Care of the Elderly, Frenchay Hospital, Bristol, UK
    Neuropathol Appl Neurobiol 26:55-66. 2000

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease
    Z K van Helmond
    Dementia Research Group, Institute of Clinical Neurosciences, Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Bristol, UK
    Neuropathol Appl Neurobiol 33:317-27. 2007
    ..Our findings suggest that alterations in the expression of vascular CAV-1 and CAV-2 are unlikely to play a role in the development of CAA in AD...
  2. ncbi request reprint Dementia with Lewy bodies
    G K Wilcock
    Department of Care of the Elderly, University of Bristol, Frenchay Hospital, BS16 1LE, Bristol, UK
    Lancet 362:1689-90. 2003
  3. ncbi request reprint Memantine for the treatment of dementia
    Gordon K Wilcock
    Department of Care of the Elderly, University of Bristol, UK
    Lancet Neurol 2:503-5. 2003
    ..Clinical trials have shown some effectiveness of memantine in the treatment of vascular dementia, although it has not been approved for use in this disorder...
  4. pmc Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group
    G K Wilcock
    Department of Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol BS16 1LE
    BMJ 321:1445-9. 2000
    ..To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease...
  5. ncbi request reprint The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials
    G K Wilcock
    Department of Care of the Elderly, University of Bristol, UK
    Int J Geriatr Psychiatry 17:175-83. 2002
    ..Data Extraction The reviewers selected trials for inclusion. Individual patient data were sought, but when these could not be retrieved summary data were extracted from published papers...
  6. ncbi request reprint Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor
    P H Holden
    Department of Medicine Care of the Elderly, Bristol Royal Infirmary, UK
    Nat Biotechnol 15:668-72. 1997
    ..Recombinant protein binds to NGF and can inhibit NGF bioactivity both in vitro and in vivo...
  7. ncbi request reprint How are quality of life ratings made? Toward a model of quality of life in people with dementia
    L M T Byrne-Davis
    Department of Care of the Elderly, Department of Clinical Science at North Bristol, University of Bristol, UK
    Qual Life Res 15:855-65. 2006
    ..The fact that so few of the participants talked about disease-orientated issues challenges the large cognitive components included in many QOL measures for use with people with dementia...
  8. ncbi request reprint APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein
    K Chalmers
    Department of Care of the Elderly, Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK
    Neuropathol Appl Neurobiol 29:231-8. 2003
    ..These findings indicate that possession of the APOE epsilon 4 allele favours vascular over parenchymal accumulation of A beta in AD. This may influence the pathogenesis of neurodegeneration in epsilon 4-associated AD...
  9. ncbi request reprint Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease
    S Williams
    Care of the Elderly, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Bristol, UK
    Neuropathol Appl Neurobiol 31:414-21. 2005
    ..We propose that both CAA and peri-vascular accumulation of hyperphosphorylated tau may be a consequence of elevated levels of soluble A beta around cortical arteries and arterioles...
  10. ncbi request reprint Neuronal death in brain infarcts in man
    S Love
    Departments of Neuropathology, Care of the Elderly, Frenchay Hospital, Bristol, UK
    Neuropathol Appl Neurobiol 26:55-66. 2000
    ....
  11. ncbi request reprint Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease
    S Love
    Department of Neuropathology, Frenchay Hospital, Bristol, UK
    Brain 122:247-53. 1999
    ..Our findings indicate that there is enhanced PARP activity in Alzheimer's disease and suggest that pharmacological interventions aimed at inhibiting PARP may have a role in slowing the progression of the disease...
  12. ncbi request reprint Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype
    S J Allen
    Department of Medicine Care of the Elderly University of Bristol, Bristol Royal Infirmary, UK
    Neurosci Lett 239:33-6. 1997
    ..This has important significance for the interpretation of the cholinergic deficits found in Alzheimer's disease...
  13. ncbi request reprint Recombinant human nerve growth factor for clinical trials: protein expression, purification, stability and characterisation of binding to infusion pumps
    S J Allen
    Molecular Neurobiology Unit, University Research Centre for Neuroendocrinology Care of the Elderly, University of Bristol, BS2 8HW, Bristol, UK
    J Biochem Biophys Methods 47:239-55. 2001
    ..Tests were also carried out to monitor release of protein from infusion pumps and catheters for intracerebroventricular administration (icv). Initial problems with non-specific binding were overcome using a blocking formula...
  14. ncbi request reprint Attentional control in Alzheimer's disease
    A D Baddeley
    Departments of Experimental Psychology and Care of the Elderly, University of Bristol, UK
    Brain 124:1492-508. 2001
    ..These results suggest a need to fractionate executive processes, and reinforce earlier evidence for a specific dual-task processing deficit in Alzheimer's disease...
  15. ncbi request reprint Failure to correlate C. pneumoniae with late onset Alzheimer's disease
    G S Taylor
    Bristol Public Health Laboratory, University of Bristol, Frenchay Hospital, Bristol, UK
    Neurology 59:142-3. 2002
  16. ncbi request reprint The pupillary light reflex in aging and Alzheimer's disease
    A Tales
    Burden Neurological Institute, Frenchay Hospital, Bristol, England, United Kingdom
    Aging (Milano) 13:473-8. 2001
    ....
  17. ncbi request reprint Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease
    S J Allen
    Molecular Neurobiology Unit, Department of Medicine Care of the Elderly, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom
    Biochem Biophys Res Commun 264:648-51. 1999
    ..This may have important consequences for the neurotrophic support of vulnerable neurons in AD...
  18. ncbi request reprint Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination
    K Vedhara
    Department of Medicine, University of Bristol, UK
    Lancet 353:627-31. 1999
    ..We investigated whether antibody responses to influenza vaccination differed between carers and a control group, and the relation of the antibody response to the hypothalamic-pituitary-adrenal (HPA) axis...
  19. ncbi request reprint Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease
    Patrick G Kehoe
    Department of Care of the Elderly, The John James Building, Frenchay Hospital, University of Bristol, UK
    Hum Genet 114:478-83. 2004
    ..These results provide an important complement to existing AD risk data, confirming that ACE harbors sequence variants that contribute to aspects of AD pathology...
  20. ncbi request reprint APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease
    Katy A Chalmers
    University of Bristol, Department of Care of the Elderly, Frenchay Hospital, Bristol BS16 1LE, UK
    Neuroreport 15:95-8. 2004
    ..Here we report that polymorphisms within the APOE promoter, ACE1 and CYP46 gene are not risk factors for AD and are not associated with parenchymal or vascular accumulation of Abeta...
  21. ncbi request reprint Premorbid effects of APOE on synaptic proteins in human temporal neocortex
    Seth Love
    Department of Neuropathology, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
    Neurobiol Aging 27:797-803. 2006
    ..01). APOE influences the concentration of synaptic proteins in normal superior temporal cortex and may thereby affect the response to injury, and the risk and outcome of a range of neurologic diseases...
  22. ncbi request reprint Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease
    Doris Culpan
    Department of Care of the Elderly, University of Bristol, John James Buildings, Frenchay Hospital, Frenchay, Bristol, BS16 1LE, UK
    Neurosci Lett 350:61-5. 2003
    ..014, Fisher's exact test) suggesting that the 2-1-2 haplotype may be protective against AD...
  23. ncbi request reprint alpha- and beta-secretase: profound changes in Alzheimer's disease
    Susan J Tyler
    Molecular Neurobiology Unit, URCN Care of the Elderly University of Bristol, Bristol Royal Infirmary, Bristol, UK
    Biochem Biophys Res Commun 299:373-6. 2002
    ..Eighty percent of Alzheimer brains examined had an increase in beta-secretase, a decrease in alpha-secretase, or both; which may account for the means by which the majority of people develop Alzheimer's disease...
  24. ncbi request reprint APOE and cerebral amyloid angiopathy in the elderly
    Seth Love
    Department of Neuropathology, Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK
    Neuroreport 14:1535-6. 2003
    ..028). Possession of epsilon4 does not by itself confer an increased risk of CAA but may be associated with reduced longevity even in the absence of AD or cerebral haemorrhage...
  25. ncbi request reprint Enhancement of antibody responses to influenza vaccination in the elderly following a cognitive-behavioural stress management intervention
    Kav Vedhara
    MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol, UK
    Psychother Psychosom 72:245-52. 2003
    ....
  26. ncbi request reprint Haplotypes extending across ACE are associated with Alzheimer's disease
    Patrick G Kehoe
    Department of Care of the Elderly, University of Bristol, The John James Building, Frenchay Hospital, Bristol, UK
    Hum Mol Genet 12:859-67. 2003
    ..Results support a model whereby decreased ACE activity may influence AD susceptibility by a mechanism involving beta-amyloid metabolism...
  27. ncbi request reprint Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis
    Christine Joffres
    Geriatric Medicine Research Unit, Queen Elizabeth II Health Sciences Centre, Halifax, Canada
    Dement Geriatr Cogn Disord 15:26-33. 2003
    ..Clinicians appear to be skeptical of cognitive changes not supported by like changes in function or behaviour...
  28. doi request reprint Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
    Gordon K Wilcock
    University of Oxford, John Radcliffe Hospital, Oxford, UK
    Lancet Neurol 7:483-93. 2008
    ..We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD...
  29. ncbi request reprint Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease
    Shabnam Baig
    Department of Clinical Science at North Bristol, Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol, UK
    Acta Neuropathol 110:393-401. 2005
    ..This could in turn lead to increased activity of the glutamatergic and other neurons onto which they synapse...
  30. ncbi request reprint Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies
    Gordon K Wilcock
    From the Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK
    J Clin Psychiatry 69:341-8. 2008
    ..The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline...
  31. ncbi request reprint Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease
    Doris Culpan
    Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Sciences at North Bristol, University of Bristol, John James Buildings, Frenchay Hospital, Frenchay, Bristol, BS16 1LE, United Kingdom
    Neurosci Lett 408:141-5. 2006
    ..Levels of IL-10 protein and gene expression examined also did not appear to be related to AD. Despite this being a relatively small sample, these data suggest that IL-10 does not play a major role in the development of AD...
  32. ncbi request reprint Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's disease
    Doris Culpan
    Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Sciences at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol, United Kingdom
    Exp Gerontol 42:538-44. 2007
    ..Our findings suggest that TNF-RI and -RII promoter gene polymorphisms and variations in protein and gene expression of these receptors are unlikely to play a major role in the development of AD...
  33. ncbi request reprint Specific AD impairment in concurrent performance of two memory tasks
    Sarah E MacPherson
    Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, UK
    Cortex 43:858-65. 2007
    ....
  34. ncbi request reprint Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
    Patrick G Kehoe
    Dementia Research Group, Institute of Clinical Neurosciences, Department of Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol
    Lancet Neurol 6:373-8. 2007
    ....
  35. ncbi request reprint Galantamine in Alzheimer's disease
    George Razay
    University of Oxford, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, UK
    Expert Rev Neurother 8:9-17. 2008
    ..The magnitude of the treatment effect is similar to that of other cholinesterase inhibitors. Adverse events experienced by patients treated with galantamine are usually mild, gastrointestinal and may improve with dose reduction...
  36. ncbi request reprint Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain
    Mia E L Blomqvist
    Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
    Neurobiol Aging 26:795-802. 2005
    ..Results indicate that alleles of IDE contribute to variability in A beta deposition in the AD brain and suggest that this relationship may have relevance for the degree of cognitive dysfunction in AD patients...
  37. ncbi request reprint Herpesviruses in brain and Alzheimer's disease
    Woan Ru Lin
    Department of Optometry and Neuroscience, UMIST, Manchester, UK
    J Pathol 197:395-402. 2002
    ....
  38. ncbi request reprint Absence of Chlamydia pneumoniae in brain of vascular dementia patients
    Matthew A Wozniak
    Department of Optometry and Neuroscience, Molecular Neurobiology Laboratory, University of Manchester Institute of Science and Technology, Manchester M60 1QD, UK
    Neurobiol Aging 24:761-5. 2003
    ..025 IFU. Our results do not support a role for Cpn in the aetiology of VaD, either in the 83% of patients in whose brains we detected CMV, or in the remaining 17% without CMV in brain...
  39. ncbi request reprint Prediction rules for computed tomography in the dementia assessment: do they predict clinical utility of CT?
    Kelly A Condefer
    Department of Care of the Elderly, Division of Medicine, University of Bristol, Bristol, UK
    Int J Geriatr Psychiatry 18:285-7. 2003
    ....
  40. ncbi request reprint The effects of galantamine treatment on caregiver time in Alzheimer's disease
    Mary Sano
    Mount Sinai School of Medicine Veterans Affairs Hospital, Bronx, NY 10468, USA
    Int J Geriatr Psychiatry 18:942-50. 2003
    ..The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers...
  41. ncbi request reprint Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism
    Hagit Katzov
    Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
    Hum Mutat 23:358-67. 2004
    ..Results indicate that variants of ABCA1 may affect the risk of AD, providing further support for a genetic link between AD and cholesterol metabolism...
  42. ncbi request reprint Clinical utility of computed tomography in the assessment of dementia: a memory clinic study
    Kelly A Condefer
    Department of Neurology, The Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Int J Geriatr Psychiatry 19:414-21. 2004
    ..To define the influence of computed tomography (CT) on clinical decision-making in the outpatient evaluation of dementia...
  43. ncbi request reprint Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials
    Anne Whitehead
    The University of Reading, Medical and Pharmaceutical Statistics Research Unit, Reading, UK
    Int J Geriatr Psychiatry 19:624-33. 2004
    ..The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD)...
  44. ncbi request reprint Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients
    Matthew A Wozniak
    Molecular Neurobiology Laboratory, Faculty of Life Sciences, The University of Manchester, Manchester, United Kingdom
    J Med Virol 75:300-6. 2005
    ..The HSV1 results confirm the original PCR findings that show the presence of HSV1 DNA sequences in many elderly brains, and indicate also that the whole functional HSV1 genome is present, and that the virus has replicated...
  45. ncbi request reprint The future of Age and Ageing
    Gordon K Wilcock
    Age Ageing 31:1. 2002